Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis

被引:438
作者
Kane, S
Huo, DZ
Aikens, J
Hanauer, S
机构
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
[3] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/S0002-9343(02)01383-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: We conducted a prospective study to determine the effects of nonadherence with mesalamine among patients with quiescent ulcerative colitis. METHODS: We followed a cohort of 99 consecutive patients who had ulcerative colitis in remission for more than 6 months and who were taking maintenance mesalamine. Medication adherence rates were calculated based on pharmacy records and a validated formula. Nonadherence was defined as refilling less than 80% of prescribed medication. Patients were followed prospectively and evaluated either in clinic or via telephone at 6, 12, and 24 months. The primary outcome was clinical recurrence of ulcerative colitis, Proportional hazards models were used to adjust for confounders. RESULTS: At 6 months, 12 patients (12%) had clinical recurrence of disease symptoms, all of whom were nonadherent with medication. At 12 months, 19 of 86 patients had recurrent disease, 13 (68%) of whom were nonadherent. Patients who were not adherent with medication had more than a five fold greater risk of recurrence than adherent patients (hazard ratio = .5.5; 95% confidence interval: 2.3 to 13; P < 0.001). CONCLUSION: Nonadherence with medication increases the risk of clinical relapse among patients with quiescent ulcerative colitis. Future research should be directed at behavioral interventions to improve adherence. (C) 2003 by Excerpta Medica, Inc.
引用
收藏
页码:39 / 43
页数:5
相关论文
共 27 条
[1]   COATED ORAL 5-AMINOSALICYLIC ACID (CLAVERSAL) IS EQUIVALENT TO SULFASALAZINE FOR REMISSION MAINTENANCE IN ULCERATIVE-COLITIS - A DOUBLE-BLIND-STUDY [J].
ARDIZZONE, S ;
PETRILLO, M ;
MOLTENI, P ;
DESIDERI, S ;
PORRO, GB .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 21 (04) :287-289
[2]   Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis [J].
Bitton, A ;
Peppercorn, MA ;
Antonioli, DA ;
Niles, JL ;
Shah, S ;
Bousvaros, A ;
Ransil, B ;
Wild, G ;
Cohen, A ;
Edwardes, MDD ;
Stevens, AC .
GASTROENTEROLOGY, 2001, 120 (01) :13-20
[3]  
Bresci G, 1997, INT J CLIN PHARM RES, V17, P17
[4]   Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease [J].
Evans, JMM ;
McMahon, AD ;
Murray, FE ;
McDevitt, DG ;
MacDonald, TM .
GUT, 1997, 40 (05) :619-622
[5]  
Felder JB, 2000, AM J GASTROENTEROL, V95, P1949
[6]   Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis [J].
Fockens, P ;
Mulder, CJJ ;
Tytgat, GNJ ;
Blok, P ;
Ferwerda, J ;
Meuwissen, SG ;
Tuynman, HARE ;
Dekker, W ;
vanHees, PAM ;
Schrijver, M ;
vanHogezand, RA ;
vanOlffen, GH ;
Breed, JGS ;
vanderHeide, H ;
Cozijin, D .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1995, 7 (11) :1025-1030
[7]   Effects of smoking on the presentation and clinical course of inflammatory bowel disease [J].
Fraga, XF ;
Vergara, M ;
Medina, C ;
Casellas, F ;
Bermejo, B ;
Malagelada, JR .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (07) :683-687
[8]  
Green JRB, 1998, ALIMENT PHARM THERAP, V12, P1207
[9]   An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis - A randomized, placebo-controlled trial [J].
Hanauer, SB ;
Sninsky, CA ;
Robinson, M ;
Powers, BJ ;
McHattie, JD ;
Mayle, JE ;
Elson, CO ;
DeMicco, MP ;
Butt, JH ;
Pruitt, RE ;
Bozdech, JM ;
Safdi, MA ;
Gurney, MS ;
Fixelle, AM ;
Levin, AI ;
Smoots, J ;
Wolf, DC .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (02) :204-+
[10]  
Irvine EJ, 1996, AM J GASTROENTEROL, V91, P1571